Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 24, 2012. The report serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMR) in the company's Ordinary Shares, specifically regarding the vesting of awards under the GlaxoSmithKline Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of executive compensation events rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific changes in share interests for two executives:
- Mr. D S Redfern: Received a cash payment for 5,027.819 notional Ordinary Shares following the vesting of 25% of an award made in 2007.
- Ms. C Thomas: Received a cash payment for 3,142.387 notional Ordinary Shares following the vesting of 25% of an award made in 2007.
Both transactions were valued at £14.39 per Ordinary Share as of September 18, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly adheres to the Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of director and managerial transactions.
Investor Verification Checklist
- Verify the share price of £14.39 per Ordinary Share as of September 18, 2012, against market data.
- Confirm the total cash payout amounts for Mr. Redfern and Ms. Thomas based on the notional share counts provided.
- Review the terms of the GlaxoSmithKline Deferred Investment Award Plan to understand the vesting schedule for awards made in 2007.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F or interim reports for financial metrics.